Arbutus Biopharma Corporation (ABUS)
- Previous Close
2.8800 - Open
2.9000 - Bid 2.8700 x 1300
- Ask 2.9000 x 1000
- Day's Range
2.8550 - 2.9280 - 52 Week Range
1.6900 - 3.2900 - Volume
366,260 - Avg. Volume
1,189,462 - Market Cap (intraday)
545.392M - Beta (5Y Monthly) 2.05
- PE Ratio (TTM)
-- - EPS (TTM)
-0.4400 - Earnings Date Aug 1, 2024 - Aug 5, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
4.40
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.
www.arbutusbio.comRecent News: ABUS
Performance Overview: ABUS
Trailing total returns as of 5/13/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ABUS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ABUS
Valuation Measures
Market Cap
544.45M
Enterprise Value
416.89M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
37.65
Price/Book (mrq)
4.75
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-29.31%
Return on Equity (ttm)
-57.54%
Revenue (ttm)
12.99M
Net Income Avi to Common (ttm)
-74.39M
Diluted EPS (ttm)
-0.4400
Balance Sheet and Cash Flow
Total Cash (mrq)
129.24M
Total Debt/Equity (mrq)
7.05%
Levered Free Cash Flow (ttm)
-46.04M
Research Analysis: ABUS
Company Insights: ABUS
ABUS does not have Company Insights